Dwight Porter, PhD
Chairman of the Board, Biothera Pharmaceuticals, Inc.
President, Applied Decision Resources
Dr. Porter is an expert in strategic and marketing planning, pricing, and product management. He received an undergraduate degree in economics at Harvard University, earned his Ph.D. at the University of Maryland, and has taught economics, pricing and management at both the undergraduate and MBA levels from 1974 to 1997. He is currently fully engaged in his consulting practice, which has included more than 100 major consulting engagements over the years. Among Dr. Porter’s career clients are 3M Company, Medtronic, Google, You Tube, Bracco Imaging, AT&T, Sprint, National Computer Systems, Harris Corporation, Northwest Airlines, Siemens, Doubleclick, Marvin Windows and Doors, The Hazelden Foundation and Lutheran Social Services.
Vice Chairman of the Board, Biothera Pharmaceuticals, Inc.
Chairman and Chief Executive Officer, Reneo Pharmaceuticals
Venture Partner, Pappas Ventures
Mr. Grey has 40 years of experience in the pharmaceutical and biotechnology industries, and has held senior positions at a number of companies. Most recently he founded and served as President and Chief Executive Officer at Lumena Pharmaceuticals, Inc., a company developing treatments for pediatric and adult orphan diseases, until its acquisition by Shire plc. Other past positions include President and Chief Executive Officer of Auspex Pharmaceuticals, Inc., President and Chief Executive Officer of SGX Pharmaceuticals, Inc., which was acquired by Eli Lilly in 2008, President and Chief Executive Officer of Trega Biosciences, Inc., which was acquired by Lion Bioscience in 2001, and President of BioChem Therapeutic Inc. For approximately 20 years, Mr. Grey served in various roles with Glaxo, Inc. and Glaxo Holdings plc, culminating in his position as Vice President, Corporate Development and Head of International Licensing.
General Partner, Canaan Partners
Mr. Ahrens is a general partner with the Canaan Partners, an early stage Life Sciences and IT venture capital fund. Since joining Canaan in 1999, Mr. Ahrens has focused on healthcare investments and has led investments in life sciences companies such as DexCom (DXCM), Revivant (acquired by ZOLL), Peninsula Pharmaceuticals (acquired by JNJ), Cerexa (acquired by FRX), Calixa (acquired by CBST), Durata Therapeutics (DRTX), and Elevation Pharmaceuticals (acquired by DNPUF). He serves on the board of several biopharmaceutical and medical device companies, including Durata Therapeutics, EndoGastric Solutions, Minimally Invasive Devices, Relievant MedSystems, Semnur and Spinifex. Prior to joining Canaan, Brent worked in both commercial and technical roles at General Surgical Innovations, Ethicon Endo-Surgery (J&J), and IAP Research. Mr. Ahrens received an MBA from the Tuck School of Business at Dartmouth College and a bachelor’s and master’s degree in Mechanical Engineering from the University of Dayton.
Annalisa Jenkins, MBBS, FRCP
Chief Executive Officer, Dimension Therapeutics
Dr. Jenkins is the CEO at leading gene therapy company Dimension Therapeutics and is a biopharma thought leader with nearly 20 years of industry experience. She has built and led teams advancing programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Prior to joining Dimension, Dr. Jenkins served as Executive Vice President, Head of Global Research and Development for Merck Serono. She also led Global Medical Affairs and Quality and was a member of Merck Serono’s Pharmaceutical Executive Committee. Previously, Dr. Jenkins had a nearly 15-year career at Bristol-Myers Squibb that culminated in position of Senior Vice President and Head of Global Medical Affairs. She received a doctorate in medicine from St. Bartholomew’s Hospital London and trained in cardiovascular medicine in the UK National Health Service.
President and Chief Operating Officer, Immuno Research Inc.
Mr. Karel has extensive senior management experience in the research, development and commercialization of beta glucan and immunotherapy technologies. From 2003-2015, he was Chief Operating Officer responsible for all research and technology development for Immuno Research Inc. (formerly Biothera Inc.). During this period, the company grew its research staff to over 25 scientists, filed over 20 patents, advanced an immunotherapy drug candidate into clinical trials for oncology which was subsequently licensed to Biothera Pharmaceuticals, Inc. Mr. Karel also was instrumental in the restructuring of the company’s businesses, including the sale of its immune health ingredient business and license of technology to Kerry Foods. In addition to his role as COO, Mr. Karel served as Chief Financial Officer at Immuno Research Inc. from 1998-2004. He has a bachelor’s degree in Accounting from the University of St. Thomas and began his career as a CPA with KPMG LLP.
Chief Executive Officer, Biothera Pharmaceuticals, Inc.
Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome Sciences, 3M Pharmaceuticals, and Immunex. He most recently served as Executive Vice President and President, Biosciences Division, at Emergent BioSolutions Inc., where he was responsible for all aspects of product development, manufacturing, and commercialization, including the advancement of partnering initiatives. Mr. Labinger has an MBA degree from J.L. Kellogg Graduate School of Management and bachelor’s degree in economics from Northwestern University.
Andrew LaFrence, CPA
Vice President of Finance and Chief Financial Officer, SurModics, Inc.
Mr. LaFrence is responsible for Finance, Information Technology, investor relationships and operations at SurModics, Inc. (NASDAQ: SRDX). Prior to joining SurModics in February 2013, he served as Chief Financial Officer for CNS Therapeutics, a venture backed intrathecal drug company that was sold to Mallinckrodt, then a subsidiary of Covidien, for $100 million in October 2012. Mr. LaFrence has more than 30 years of financial and management experience. He was an audit partner at KPMG LLP where he focused on supporting venture-backed, high-growth medical technology, pharmaceutical, biotech and clean tech private and public companies. Mr. LaFrence is a certified public accountant and has a bachelor’s degree in accounting and a minor in business administration from Illinois State University.
Alex Giaquinto, PhD
Former Senior Vice President, Schering-Plough
Dr. Giaquinto has held many positions during his career at Schering-Plough Corporation from 1973 until his retirement in 2004. As Senior Vice President of Worldwide Regulatory Affairs for Schering-Plough Research Institute, he was instrumental in establishing the development and regulatory strategies for the approvals of 74 New Drug Applications (NDAs), 9 Biologic Licensing Applications (BLAs), and 28 Abbreviated New Drug Applications (ANDs). Other positions Dr. Giaquinto held at Schering-Plough included Senior Vice President of Global Compliance, Associate Director of Pharmaceutical Research and Development, Clinical Manufacturing, Package Development and Aerosol Process Development. He is currently the Chairman of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers Association. Dr. Giaquinto received a doctorate in Pharmaceutics from University of Connecticut and a bachelor’s degree in Pharmacy from St. John’s University College of Pharmacy.
Chairman and Chief Executive Officer, Immuno Research Inc.
Mr. Mueller currently has dual positions as Chairman and Chief Executive Officer of Immuno Research Inc. and Biothera Holding Corp. Previously Mr. Mueller was President of Biothera Holding’s global immune health ingredient business (Biothera Health Inc.) with sales in more than 60 countries. He held numerous other executive management and board positions during his career, including: President, President, Textron Omniquip Alliance Group (NYSE: TXT); President/CEO, Weslock Inc.; Chairman/CEO, Playcore Inc. (AMEX: PCO); and Managing Director/President, Toro-Wheel Horse (NYSE: TTC). He has also held a number of senior management positions with both Toro and 3M Company earlier in his career. He received a bachelor’s degree from the Carlson School of Management, University of Minnesota.
President and Chief Executive Officer, Regenacy Pharmaceuticals, LLC
Mr. Ogier has nearly 30 years of life sciences industry experience developing and commercializing small molecule drugs, therapeutic stem cell and gene therapies, monoclonal antibodies, and medical devices for the treatment of a broad range of diseases, including hematologic and solid tumor cancers. Mr. Ogier is President and Chief Executive Officer of Regency Pharmaceuticals, which was spun off from Acetylon Pharmaceuticals, a company Mr. Ogier co-founded in 2008 and was recently acquired by Celgene. Previously, Mr. Ogier held a number of executive management positions including President, Chief Executive Officer and Director, Arbios Systems, Inc. (NASDAQ: ABOS.OB); President, Chief Executive Officer and Director, GENETIX Pharmaceuticals, Inc., (now Bluebird Bio, NASDAQ: BLUE); President, Chief Executive Officer and Director, Eligix, Inc. (formerly Coulter Cellular Therapies, Inc.); and President and Chief Operating Officer, BioTransplant Inc. Mr. Ogier also held several management positions earlier in his career at Baxter Healthcare Corp. He has an MBA from the Yale School of Management and a bachelor’s degree in Chemistry from Williams College.
Bruno Osterwalder, MD
Former SVP, Senior Strategic Advisor Oncology, Global Research and Drug Development, Merck Serono
Dr. Osterwalder has more than 25 years of pharmaceutical industry experience that includes all drug development stages, from research transition into humans with an emphasis on translational medicine, to global registrations and life cycle management. He presently is a consultant on global drug development strategies in oncology, hematology and immune-oncology. Previously he held a senior leadership role in global hemato-oncology and immune-oncology drug development during his six years at Merck Serono. Before that he held various positions with increasing responsibilities in global drug development at F. Hoffmann-Roche with a focus on novel drugs in hematology, oncology and renal and cancer anemia. Dr. Osterwalder has 15 years academic/clinical practice in internal medicine, hematology and oncology (Swiss board certifications). Dr. Osterwalder received a medical degree from the University of Zurich.